Events and Presentations

Date	Title
September 17, 2020	Investor Presentation 2.5 MB
July 13, 2020	ISTH – Phase 1 study to evaluate the pharmacokinetics, pharmacodynamics, and safety of ascending doses of subcutaneous marzeptacog alfa (activated) in adult subjects with hemophilia 1 MB
July 13, 2020	ISTH – Marzeptacog alfa (activated) population pharmacokinetics (PK): Simulations for dose selection in Phase 3 trials 2.1 MB
June 19, 2020	WFH - Combination of a Novel Chimeric AAV Capsid and Potency Enhanced FIX Variant for Hemophilia B Gene Therapy 2 MB
June 18, 2020	Raymond James Human Health Innovation Conference Presentation 2.6 MB
June 15, 2020	WFH - Phase 2B Trial to Evaluate the Safety and Factor IX Levels of a Daily Subcutaneous Prophylaxis Treatment Regimen of Dalcinonacogalfa in Hemophilia B 2.1 MB
December 08, 2019	ASH - The Combination of Marzeptacog Alfa (Activated) or Eptacog Alfa (Activated) with Emicizumab Appears Comparable in the Thrombin Generation Test in Hemophilia A 1.7 MB
December 08, 2019	ASH - Fast Onset of Action of Subcutaneously Administered Marzeptacog Alfa (Activated) Supports On-Demand Treatment in Hemophilia A Mice 2.3 MB
September 15, 2019	Catalyst Biosciences at the ASBMB Conference Presentation 12.2 MB
August 21, 2019	HDD - A Tale of Two Subcutaneous Coagulation Factors 3.5 MB
August 20, 2019	HDD - Understanding Immunogenicity in Next Generation Factor Replacement Prophylaxis 14.4 MB
August 15, 2019	KOL event for analysts and investors on MarzAA, next-generation Factor VIIa Marzeptacog alfa (activated) in individuals with bleeding disorders Presentation 15.3 MB